SEC probe hits Galena hard

Shares of Galena Biopharma went into a tailspin on 18 March, plunging 21% after the company revealed the Securities and Exchange Commission (SEC) had opened an investigation into the firm and an outside investor relations company the biotech retained last year.

Shares of Galena Biopharma went into a tailspin on 18 March, plunging 21% after the company revealed the Securities and Exchange Commission (SEC) had opened an investigation into the firm and an outside investor relations company the biotech retained last year.

Galena's shares closed at $2.82 on 18 March, down 12.4%, or 40 cents.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category